載入...
The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains
Multiple myeloma (MM) is a tumor of plasmablasts/plasma cells (PCs) characterized by the expansion of malignant PCs with complex genetic aberrations in the bone marrow (BM). Recent reports, by us and others, have highlighted the polycomb group (PcG) proteins as potential targets for therapy in MM. T...
Na minha lista:
發表在: | Oncotarget |
---|---|
Main Authors: | , , , , , , , , , , , |
格式: | Artigo |
語言: | Inglês |
出版: |
Impact Journals LLC
2017
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5732762/ https://ncbi.nlm.nih.gov/pubmed/29262596 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21909 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|